Stock TFFP TFF PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
3.01 USD +1.35% Intraday chart for TFF Pharmaceuticals, Inc. -7.11% -57.12%
Apr. 15 TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions CI
Apr. 08 TFF Pharmaceuticals Files Equities Shelf MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
AQ
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions
CI
TFF Pharmaceuticals Files Equities Shelf
MT
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M
MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Roth MKM Cuts TFF Pharmaceuticals' Price Target to $44 From $56, Maintains Buy Rating
MT
Transcript : TFF Pharmaceuticals, Inc. - Special Call
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
AQ
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs
CI
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
AQ
TFF Pharmaceuticals Sells Stock in Registered Direct Offering
MT
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
AQ
TFF Pharmaceuticals Announces Update on Clinical Programs
AQ
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs
CI
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
AQ
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference 
AQ
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TFFP Stock
  4. News TFF Pharmaceuticals, Inc.